拜瑞妥使用方法

(Rivaroxaban) can interrupt the intrinsic and extrinsic pathways of the coagulation cascade by inhibiting factor Xa, inhibiting thrombin generation and thrombosis. Xarelto does not inhibit thrombin (activated factor II) and has no proven effect on platelets. A dose-dependent inhibition of factor Xa activity by Xarelto has been observed in humans. Today we will learn more about how to use Xarelto.

1. Xarelto (rivaroxaban) to prevent venous thrombosis in adult patients undergoing elective hip or knee replacement surgery:

The recommended dose is 10 mg of Xarelto taken orally once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery.

For patients undergoing major hip surgery, the recommended course of treatment is 35 days.

For patients undergoing major knee surgery, the recommended course of treatment is 12 days.

If a missed dose occurs, patients should take Xarelto immediately and continue taking the dose once daily the next day.

2. Xarelto (rivaroxaban) treats DVT (venous thrombosis) and reduces the risk of acute DVT recurrence and PE:

The recommended dose for initial treatment of acute DVT is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of recurrent DVT and PE.

3. Used in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism:

The recommended dose of Xarelto (rivaroxaban) is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and elderly patients (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

In addition, things to note about Xarelto (rivaroxaban) are: 1. Patients with liver and renal insufficiency can significantly increase the blood concentration of this product, leading to an increased risk of bleeding. 2. Patients with active bleeding; patients with liver disease who have coagulation abnormalities and clinically relevant bleeding risks; 3. Contraindicated in pregnant and lactating women.

Xarelto is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Xarelto does not inhibit thrombin and has no proven effect on platelets.

The above is the content of how to take Rivaroxaban. I hope it can help you!

Recommended related hot articles: /newsDetail/76582.html